May 28, 2009
Phase 3 study of Nexavar and Tarceva for primary liver cancer
Nexavar is an oral multikinase inhibitor targeting both the tumor cell and tumor vasculature. Tarceva is a once-daily oral formulation designed to inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cell.
For more information call (866) NEXAVAR or visit www.nexavar.com.